Jan P Nicolay
Overview
Explore the profile of Jan P Nicolay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
685
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lehmann J, Dragan T, Rammant E, de Ligt K, Lai-Kwon J, Lidington E, et al.
Eur J Cancer
. 2025 Mar;
220:115333.
PMID: 40043551
Background: Using patient reported-outcome measures (PROMs) in routine care has significant potential to benefit patients with cancer, but it is unclear how widely they are used in practice. Methods: We...
2.
Costanza M, Giordano C, von Brunneck A, Zhao J, Makky A, Vinh K, et al.
Br J Dermatol
. 2025 Mar;
PMID: 40036608
Background: Prognosis and quality of life of advanced cutaneous T cell lymphoma (CTCL) patients, in particular those with Sézary syndrome (SS) and advanced-stage mycosis fungoides (MF), are poor. Monoclonal antibodies...
3.
Ozistanbullu D, Wilhelm R, Reichenbach G, Doll M, Bahrami K, Zoller N, et al.
Blood Adv
. 2025 Feb;
PMID: 40020159
Cutaneous T-cell lymphomas (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS), are rare hematological malignancies with limited curative treatment options. Despite early-stage responsiveness, these malignancies often relapse in advanced...
4.
Assaf C, Booken N, Dippel E, Dobos G, Eich H, Klemke C, et al.
J Dtsch Dermatol Ges
. 2024 Dec;
23(3):341-354.
PMID: 39723687
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of the heterogeneous group of cutaneous T-cell lymphomas (CTCL). With the expansion of the biologic treatment landscape, new...
5.
Cankaya R, Kleiner P, Nicolay J, Moritz R, Dobos G
Acta Derm Venereol
. 2024 Nov;
104:adv42348.
PMID: 39601370
No abstract available.
6.
Sener O, Melchers S, Tengler L, Beltzig P, Albrecht J, Tumen D, et al.
Leukemia
. 2024 Nov;
39(2):438-450.
PMID: 39580583
Primary cutaneous T cell lymphomas (CTCL) are characterized by high relapse rates to initially highly effective therapies. Combination therapies have proven beneficial, particularly if they incorporate extracorporeal photopheresis (ECP). The...
7.
Elsayad K, Guenova E, Fournier B, Fernandes C, Clementel E, Papadavid E, et al.
Int J Radiat Oncol Biol Phys
. 2024 Nov;
121(4):1006-1010.
PMID: 39549760
Purpose: We aim to determine the current treatment patterns and recommendations among physicians for cutaneous lymphomas and to identify the types of skin lymphomas for which existing radiation regimens need...
8.
Gniadecki R, Guenova E, Querfeld C, Nicolay J, Scarisbrick J, Sokol L
Br J Dermatol
. 2024 Nov;
192(3):381-389.
PMID: 39545505
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of diseases characterized by abnormal neoplastic T-cell growth in the skin. Mycosis fungoides (MF), the most common CTCL, manifests as erythematous skin...
9.
Elsayad K, Guenova E, Assaf C, Nicolay J, Trautinger F, Stadler R, et al.
Eur J Cancer
. 2024 Oct;
212:115064.
PMID: 39418694
The number of primary cutaneous lymphoma patients receiving low-dose radiotherapy is increasing, though controlled clinical trials defining the standard radiation dose for each specific entity have not yet been completed....
10.
Hansen-Abeck I, Geidel G, Abeck F, Kott J, Cankaya R, Dobos G, et al.
J Dtsch Dermatol Ges
. 2024 Oct;
22(11):1489-1497.
PMID: 39358932
Background: Interferon-alpha is an important therapeutic option for the treatment of the cutaneous T-cell lymphomas (CTCL). Since the approved recombinant interferon-α-2a (IFN-α2a) has no longer been produced since January 2020,...